Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

43%

3 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

4 recruiting1 with results

Enrollment Performance

Analytics

Phase 4

3(100.0%)

3Total

Phase 4(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT03263130Recruiting

Site and Mechanism(s) of Expiratory Airflow Limitation in COPD, Emphysema and Asthma-COPD Overlap

Role: lead

NCT03839992Recruiting

Detection of Unsuspected Small Airways Obstruction in Cystic Fibrosis

Role: lead

NCT01225913Phase 4Recruiting

Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

Role: lead

NCT00576069Recruiting

Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

Role: lead

NCT00569270Phase 4Completed

Dynamic Hyperinflation and Tiotropium

Role: lead

NCT00570544Completed

Tiotropium Induced Bronchodilation in Lung CT Scored Emphysema

Role: lead

NCT00575861Phase 4Completed

Zileuton and Exhaled Nitric Oxide in Asthmatics

Role: lead

All 7 trials loaded